This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| vitamin K | |
|---|---|
| Name | Vitamin K |
| Caption | Chemical structures and biosynthetic precursors |
| Discovered | 1929 |
| Discoverer | Henrik Dam, Edward Adelbert Doisy |
| Othernames | Phylloquinone, Menaquinone, Menadione |
| Solubility | Fat-soluble |
vitamin K Vitamin K is a family of fat-soluble compounds required for post-translational modification of specific proteins involved in hemostasis, bone metabolism, and cellular regulation. First characterized in the late 1920s, the vitamin has played a central role in research connected to Nobel Prize in Physiology or Medicine laureates and the discovery of coagulation pathways studied by investigators at institutions such as Carlsberg Laboratory and Washington University in St. Louis. Clinical and nutritional interest spans public health agencies, surgical practice at centers like Mayo Clinic, and neonatal care in hospitals including Great Ormond Street Hospital.
Vitamin K refers to a set of naturally occurring and synthetic compounds that function as cofactors for gamma-glutamyl carboxylase in the post-translational carboxylation of glutamate residues. The discovery narrative involves experiments in avian models conducted by Henrik Dam and biochemical characterization by Edward Adelbert Doisy, leading to recognition by the Nobel Committee. Modern research integrates work from laboratories at Harvard Medical School, Karolinska Institutet, and Max Planck Society to delineate its role in coagulation cascade studies influenced by the legacy of Paul Morawitz and contemporary clotting factor research at institutions such as St Bartholomew's Hospital.
Chemically, the vitamin K family comprises phylloquinone (K1), menaquinones (K2, MK-n), and synthetic menadione (K3). Structural elucidation employed techniques advanced at Royal Society-affiliated laboratories and universities like University of Cambridge and ETH Zurich, revealing a 2-methyl-1,4-naphthoquinone core with varying isoprenoid side chains. Phylloquinone is abundant in chloroplast-rich tissues investigated by botanists linked to Kew Gardens, while menaquinones derive from bacterial biosynthesis characterized in studies at Pasteur Institute and Columbia University. Synthetic analogs such as menadione have been examined in pharmacology departments at University of California, San Francisco and toxicology units at Johns Hopkins University.
Vitamin K operates as an essential cofactor for the enzyme gamma-glutamyl carboxylase (GGCX) located in the endoplasmic reticulum; this enzyme catalyzes conversion of glutamate to gamma-carboxyglutamate (Gla) residues in vitamin K–dependent proteins. Key substrate proteins include clotting factors synthesized in the liver, a process historically mapped in research at Addenbrooke's Hospital and Royal Infirmary of Edinburgh. Other targets encompass osteocalcin in bone matrix studies associated with University of Oxford and matrix Gla protein examined by teams at Karolinska Institutet. The vitamin K cycle, involving vitamin K epoxide reductase (VKOR), was elucidated with contributions from researchers at University of Cambridge and pharmaceutical investigations at GlaxoSmithKline.
Dietary phylloquinone is abundant in leafy greens documented in agricultural studies by United States Department of Agriculture, including kale, spinach, and collard greens evaluated by extension services at Land Grant Universities. Menaquinones are found in fermented foods analyzed by food science groups at University of Copenhagen and in gut microbiota research at Wellcome Sanger Institute. Daily intake recommendations have been issued by agencies such as World Health Organization and Institute of Medicine with adjustments for populations monitored by Centers for Disease Control and Prevention. Historical dietary deficiency mapping involved public health campaigns from Ministry of Health (United Kingdom) and nutritional surveys coordinated by Food and Agriculture Organization.
Absorption of fat-soluble vitamin K species occurs in the small intestine via micelle-mediated uptake facilitated by bile salts studied in hepatic physiology research at Mayo Clinic and Cleveland Clinic. Transport kinetics engage chylomicron pathways characterized in lipoprotein research at Rockefeller University and hepatic uptake involving receptors described by investigators at Scripps Research. The hepatic recycling of vitamin K through VKOR is the target of anticoagulant drugs identified in studies at University of Wisconsin–Madison and pharmaceutical work at Boehringer Ingelheim. Tissue distribution differences between K1 and K2 isoforms were delineated in metabolic tracing studies at Imperial College London.
Deficiency manifests as impaired gamma-carboxylation of clotting factors, leading to bleeding diatheses observed in neonates and patients with malabsorption syndromes treated at centers such as Great Ormond Street Hospital and Addison's Disease Clinic-linked endocrinology units. Historical outbreaks of hemorrhagic disease linked to dietary insufficiency were documented in reports by Ministry of Health (United Kingdom) and military medical corps during campaigns like those recorded in World War II epidemiology. Long-term implications include vascular calcification and osteoporosis explored by research groups at Mayo Clinic and National Institutes of Health, with population-level evidence aggregated by teams at Harvard T.H. Chan School of Public Health.
Pharmacologically, vitamin K is used to reverse warfarin-associated coagulopathy; clinical protocols were standardized through trials conducted at Cleveland Clinic and Brigham and Women's Hospital. VKOR inhibition underlies anticoagulant therapies originating from studies involving Coumarin derivatives developed by industry players like Bayer AG. Intravenous and oral formulations of phylloquinone are produced and regulated in pharmacopeias overseen by World Health Organization and European Medicines Agency. Investigational uses in bone health have been assessed in randomized trials sponsored by institutions such as University of Tokyo and Kyoto University, while toxicology of synthetic menadione was characterized in safety assessments at Food and Drug Administration and veterinary toxicology reports from Royal Veterinary College.
Category:Vitamins